Ritedose, the Leading Pharmaceutical Manufacturer (CDMO) Specializing in Sterile Blow-Fill-Seal, Expands Its BFS Capacity to Meet the Growing Demand for Ophthalmic and Respiratory Medications
Ritedose, the Leading Pharmaceutical Manufacturer (CDMO) Specializing in Sterile Blow-Fill-Seal, Expands Its BFS Capacity to Meet the Growing Demand for Ophthalmic and Respiratory Medications
-With the new expansion, Ritedose's total BFS capacity will exceed 2.6 billion units—solidifying Ritedose as the largest BFS manufacturer in the United States
-憑藉新擴張，Ritedose的BFS總產能將超過26億個單位，鞏固其作爲美國最大的BFS製造商的地位。
-Ritedose has co-developed and commercialized more than 80% of new products introduced in BFS in the past decade
-Ritedose公司在過去十年中，BFS推出的新產品中有80%以上是由Ritedose公司進行聯合研發和商業化的。。
COLUMBIA, S.C., June 20, 2024 /PRNewswire/ -- The Ritedose Corporation (Ritedose), the leading contract development and manufacturing organization (CDMO) specializing in sterile Blow Fill Seal (BFS) production, announces a significant expansion of its production capabilities to meet the demand for ophthalmic and respiratory medications.
南卡羅來納州，2024年6月20日/美通社—Ritedose公司（簡稱：Ritedose）、領先的合同開發和製造組織（CDMO），專門從事無菌吹塑封閉（BFS）生產，宣佈顯着擴展生產能力以滿足眼科和呼吸道藥物的需求。
Ritedose has expanded its sterile Blow-Fill-Seal (BFS) capabilities, and the new equipment is expected to begin production in August of this year. The addition of another 180-million-unit dose capacity for ophthalmic and respiratory medications underscores the company's commitment to meeting the increasing demand from cutting edge ophthalmic and respiratory drug developers for high-quality, sterile unit dose solutions.
Ritedose擴大了其無菌吹塑封閉（BFS）的生產能力，新設備預計將於今年8月開始生產。增加另外1.8億單位的劑量產能，供應眼科和呼吸道藥物，凸顯公司滿足最前沿的眼科和呼吸道藥物開發商對高質量無菌單劑量解決方案不斷增長的需求。
Investment in expansions reflect our commitment to providing reliable, quality unit dose solutions for our customers.
擴張投資反映了我們致力於爲客戶提供可靠，高質量單劑量解決方案的承諾。
"This expansion marks a pivotal moment in our company's history," said CEO of Ritedose Jody Chastain. "We're passionately dedicated to advancing the health and well-being of patients across the United States—it's why we come to work every single day. We are perfectly positioned to support our partners and deliver quality medications, and both they and our patients count on us to be steps ahead in capacity, capabilities and without a doubt, quality. It's our forward-looking strategy and commitment that has allowed us to maintain a 100% customer retention rate over the past 25 years."
Ritedose公司首席執行官Jody Chastain表示: “這次擴張標誌着我公司歷史上的一個關鍵時刻。我們熱情地致力於推進美國患者的健康和福祉——這就是我們每一天上班的原因。我們的定位非常完美，支持我們的合作伙伴，並提供高質量的藥品。他們和我們的患者都信賴我們擁有超前的產能、技術能力和無疑的質量。正是我們前瞻的戰略和承諾使我們在過去25年中保持了100%的客戶保留率。”
The new capacity will be integrated into Ritedose's state-of-the-art manufacturing facility in Columbia, SC, which adheres to the highest standards of quality and compliance. The facility is equipped with cutting-edge technology and staffed by a team of highly skilled professionals committed to excellence in sterile manufacturing. With an emphasis on providing an exceptional workplace for its employees, Ritedose remains a leading employer in the Midlands, employing over 600 people.
新產能將整合到Ritedose公司位於Columbia的最先進的製造工廠中，該工廠符合最高的質量和合規標準。工廠配備先進設備，由一支高素質的專業人員團隊擔任，致力於無菌製造的卓越性能。Ritedose公司專注於爲員工提供卓越的工作場所，是Midlands傑出的僱主之一，擁有超過600名員工。
This strategic expansion enhances the Company's ability to serve its customers more efficiently and ensure a consistent supply of critical medications. Increasing capacity also allows Ritedose to respond to a rising need for ophthalmic and respiratory treatments due to an increasing prevalence of respiratory diseases and an aging population requiring advanced eye care solutions.
這次戰略性擴張增強了公司更高效地服務客戶和確保關鍵藥物的持續供應能力的能力。增加產能還允許Ritedose公司響應呼吸道疾病普及率上升和老年人對先進眼部護理解決方案的需求不斷增長的趨勢。
"Ritedose has co-developed and commercialized more than 80% of new products introduced in a BFS dosage form for the past 10 years. This track record of successful partnerships highlights the Company's role as a key innovator in the BFS sector and a trusted collaborator for pharmaceutical companies. To remain laser focused on growing our capacity, innovation and specialty in BFS, we are making a strategic decision to pivot the necessary resources away from our 503B Outsourcing Division—concentrating all resources to FDA approved drug products," Chastain continued.
Chastain繼續說道:“Ritedose公司在過去10年中推出的新產品中，超過80%是使用BFS劑型進行聯合開發和商業化的。這一成功合作的記錄突顯了公司在BFS行業中的關鍵創新者和藥品公司值得信賴的合作伙伴的角色。爲了保持對BFS劑型產能、創新和專業的關注，我們正在做出戰略性決策，將必要的資源從我們的503B外包部門轉移，集中所有資源用於FDA批准的藥物產品。”
Ritedose's continued investment in capacity expansion and technological innovation reflects its unwavering commitment to its mission of providing reliable, high-quality unit dose solutions for the pharmaceutical industry.
Ritedose公司繼續投資於產能擴張和技術創新，反映了其對爲製藥行業提供可靠、高質量單劑量解決方案的使命的堅定承諾。
About The Ritedose Corporation
Ritedose is the largest sterile contract development manufacturing organization (CDMO) in the US specializing in sterile Blow Fill Seal (BFS) technology that ensures sterile, consistent, and safe unit dose delivery. The company's process guides the development of molecules from clinical trials to commercialization of branded and generic inhalation and ophthalmic medications and compounding single-unit dose syringes. With a focus on quality, innovation, and customer satisfaction, Ritedose partners with leading pharmaceutical companies to deliver safe, effective, and reliable medications that improve patient outcomes. For more information about Ritedose and its services: visit Ritedose.com
關於Ritedose公司
Ritedose公司是美國最大的無菌合同開發製造組織（CDMO），專門從事無菌吹塑封閉（BFS）技術，從臨床試驗到品牌和非專利化口服和眼科藥物的商業化，以及編制單劑量注射器。以質量、創新和客戶滿意度爲重點，Ritedose公司與領先的製藥公司合作，提供安全、有效和可靠的藥物，改進患者的治療效果。了解有關Ritedose公司及其服務的更多信息，請訪問Ritedose.com
Media Contact:
媒體聯繫人：
Alex Keown
Inspire Agency on Behalf of Ritedose
630.346.5141
[email protected]
Alex Keown
Inspire Agency代表Ritedose公司
630.346.5141
[email protected]
SOURCE Ritedose
資料來源：Ritedose
譯文內容由第三人軟體翻譯。